|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1995-11-27 |
Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD) - CONNECT-IBD
A PHASE III RANDOMISED, MULTICENTRE, DOUBLE-BLIND, THERAPEUTIC EQUIVALENCE STUDY OF BIOSIMILAR G-CSF (PLIVA/MAYNE FILGRASTIM) VERSUS NEUPOGEN (FILGRASTIM – AMGEN) IN SUBJECTS RECEIVING DOXORUBICIN AND DOCETAXEL AS A COMBINATION CHEMOTHERAPY REGIMEN FOR BREAST CANCER
100 项与 Hospira UK Ltd. 相关的临床结果
0 项与 Hospira UK Ltd. 相关的专利(医药)
100 项与 Hospira UK Ltd. 相关的药物交易
100 项与 Hospira UK Ltd. 相关的转化医学